Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Contrast-Enhanced Ultrasound vs MRI for TACE Evaluation in HCC
NCT03045497Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Dec 2012
- Primary completion
- Dec 2013
- Modality
- Drug Delivery Systems
01
Overview
Phase 1, open-label, single-arm trial of perflutren lipid microspheres in hepatocellular carcinoma (HCC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Ability of contrast-enhanced ultrasound to predict response to transarterial chemoembolization with drug eluting beads at 1 month. Started Dec 2012; status: completed.
02
Drugs
perflutren lipid microspheres
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03045497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03045497.